Log in

NASDAQ:XFORX4 Pharmaceuticals Stock Price, Forecast & News

$8.81
-0.06 (-0.68 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.60
Now: $8.81
$9.00
50-Day Range
$8.17
MA: $9.24
$9.98
52-Week Range
$5.84
Now: $8.81
$18.75
Volume68,213 shs
Average Volume68,020 shs
Market Capitalization$142.19 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XFOR
CUSIPN/A
CIKN/A
Phone857-529-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.36 per share

Profitability

Net Income$-52,810,000.00

Miscellaneous

Employees63
Market Cap$142.19 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive XFOR News and Ratings via Email

Sign-up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.

X4 Pharmaceuticals (NASDAQ:XFOR) Frequently Asked Questions

How has X4 Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

X4 Pharmaceuticals' stock was trading at $8.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XFOR shares have increased by 2.7% and is now trading at $8.81. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of X4 Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for X4 Pharmaceuticals.

When is X4 Pharmaceuticals' next earnings date?

X4 Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for X4 Pharmaceuticals.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals Inc (NASDAQ:XFOR) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.27. The business earned $3 million during the quarter. View X4 Pharmaceuticals' earnings history.

What price target have analysts set for XFOR?

7 brokerages have issued twelve-month target prices for X4 Pharmaceuticals' shares. Their forecasts range from $15.00 to $27.00. On average, they anticipate X4 Pharmaceuticals' stock price to reach $19.67 in the next year. This suggests a possible upside of 123.2% from the stock's current price. View analysts' price targets for X4 Pharmaceuticals.

Has X4 Pharmaceuticals been receiving favorable news coverage?

News headlines about XFOR stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. X4 Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutX4 Pharmaceuticals.

Who are some of X4 Pharmaceuticals' key competitors?

What other stocks do shareholders of X4 Pharmaceuticals own?

Who are X4 Pharmaceuticals' key executives?

X4 Pharmaceuticals' management team includes the following people:
  • Dr. Paula Ragan, Founder, CEO, Pres, Sec. & Director (Age 50)
  • Dr. Renato T. Skerlj, Founder, Sr. VP of R&D and Member of Scientific Advisory Board
  • Mr. Adam S. Mostafa, CFO, Treasurer & Assistant Sec. (Age 40)
  • Dr. Mary DiBiase, Sr. VP of Technical Operations & Quality
  • Mr. Derek M. Meisner Esq., J.D., Gen. Counsel (Age 49)

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

Who are X4 Pharmaceuticals' major shareholders?

X4 Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.43%), Sphera Funds Management LTD. (5.41%), RA Capital Management L.P. (3.73%), AXA (3.11%), Cormorant Asset Management LP (2.12%) and State Street Corp (1.70%). View institutional ownership trends for X4 Pharmaceuticals.

Which institutional investors are selling X4 Pharmaceuticals stock?

XFOR stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, Morgan Stanley, New York State Common Retirement Fund, UBS Group AG, ClariVest Asset Management LLC, and Deutsche Bank AG. View insider buying and selling activity for X4 Pharmaceuticals.

Which institutional investors are buying X4 Pharmaceuticals stock?

XFOR stock was bought by a variety of institutional investors in the last quarter, including AXA, RA Capital Management L.P., Sphera Funds Management LTD., State Street Corp, Cormorant Asset Management LP, BlackRock Inc., Geode Capital Management LLC, and Nuveen Asset Management LLC. View insider buying and selling activity for X4 Pharmaceuticals.

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $8.81.

How big of a company is X4 Pharmaceuticals?

X4 Pharmaceuticals has a market capitalization of $142.19 million. The company earns $-52,810,000.00 in net income (profit) each year or ($4.63) on an earnings per share basis. X4 Pharmaceuticals employs 63 workers across the globe.

What is X4 Pharmaceuticals' official website?

The official website for X4 Pharmaceuticals is www.x4pharma.com.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-529-8300 or via email at [email protected]

This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.